

REFERENCES

- [1] SCHOOL OF BUSINESS, GALGOTIAS UNIVERSITY and S. Kumari, "PHARMACEUTICAL INDUSTRY ANALYSIS: A COMPREHENSIVE REVIEW OF MARKET TRENDS, COMPETITIVE LANDSCAPE, AND FUTURE OUTLOOK," *IJSREM*, vol. 08, no. 04, pp. 1–5, May 2024, doi: 10.55041/IJSREM32665.
- [2] A. Goryachev *et al.*, "Research of the dynamics of wholesale segment concentration level in the regional pharmaceutical market," *PHAR*, vol. 71, pp. 1–8, Oct. 2024, doi: 10.3897/pharmacia.71.e125385.
- [3] I. Demetz, "Lonza seeks deals as it exits health and ingredients to focus on contract development," *Reuters*, Dec. 12, 2024. Accessed: Dec. 15, 2024. [Online]. Available: <https://www.reuters.com/business/healthcare-pharmaceuticals/lonza-exit-capsules-health-ingredients-business-focus-contract-development-2024-12-12/>
- [4] P. Yadav and L. Smith, "Pharmaceutical Company Strategies and Distribution Systems in Emerging Markets," in *Encyclopedia of Health Economics*, Elsevier, 2014, pp. 1–8. doi: 10.1016/B978-0-12-375678-7.01218-9.
- [5] "USA - Current trends and regulatory aspects of nutraceutical: A comprehensive review — Food Compliance International." Accessed: Jan. 02, 2025. [Online]. Available: <https://foodcomplianceinternational.com/industry-insight/scholarly-articles/3573-usa-current-trends-and-regulatory-aspects-of-nutraceutical-a-comprehensive-review>
- [6] "COMPREHENSIVE REVIEW ON NUTRACEUTICALS," *IJBPAS*, vol. 10, no. 12 (SPECIAL ISSUE), Dec. 2021, doi: 10.31032/IJBPAS/2021/10.12.1017.
- [7] "The COVID-19 pandemic and continuing challenges to global health." Accessed: Dec. 04, 2024. [Online]. Available: <https://www.who.int/about/funding/invest-in-who/investment-case-2.0/challenges>
- [8] "How Covid-19 could disrupt pharmaceutical supply chains," *Quartz*. Accessed: Dec. 18, 2024. [Online]. Available: <https://qz.com/1826939/how-covid-19-could-disrupt-pharmaceutical-supply-chains>
- [9] "Lonza | CDMO Development and Manufacturing for a Healthier World," Lonza | CDMO Development and Manufacturing for a Healthier World. Accessed: Dec. 15, 2024. [Online]. Available: <https://www.lonza.com/>
- [10] "Empty Capsules Market Size, Growth | Global Report [2032]." Accessed: Jan. 02, 2025. [Online]. Available: <https://www.fortunebusinessinsights.com/industry-reports/empty-capsules-market-101171>
- [11] "Capsules & Health Ingredients | Lonza." Accessed: Jan. 18, 2025. [Online]. Available: <https://www.lonza.com/careers/divisions/capsules-health-ingredients>
- [12] "Lonza bulks up with \$5.5B deal for Capsugel | Fierce Pharma." Accessed: Jan. 18, 2025. [Online]. Available: <https://www.fiercepharma.com/manufacturing/lonza-bulks-up-5-5b-deal-for-capsugel>
- [13] "industry." Accessed: Jan. 03, 2025. [Online]. Available: <https://dictionary.cambridge.org/dictionary/english/industry>
- [14] A. A. Signore and T. Jacobs, Eds., *Good design practices for GMP pharmaceutical facilities*, Second edition. in *Drugs and the pharmaceutical sciences*, no. volume 214. Boca Raton: Taylor & Francis, 2017.



- [15] A. A. Thompson, M. A. Peteraf, J. E. Gamble, and A. J. Strickland, *Crafting and executing strategy: the quest for competitive advantage: concepts and cases*, 22nd edition. New York, NY: McGraw-Hill Education, 2020.
- [16] A. Campbell, *Strategy for the corporate level: where to invest, what to cut back and how to grow organisations with multiple divisions*, 2nd edition, 2nd ed. San Francisco, CA: Jossey-Bass, 2014.
- [17] C. Lin, H. Tsai, Y. Wu, and M. Kiang, "A fuzzy quantitative VRIO-based framework for evaluating organizational activities," *Management Decision*, vol. 50, no. 8, pp. 1396–1411, Aug. 2012, doi: 10.1108/00251741211261999.
- [18] J. B. Barney, *Gaining and sustaining competitive advantage*, Fourth edition, Pearson new international edition. Harlow: Pearson, 2014.
- [19] M. I. Alhojailan, "Thematic analysis: a critical review of its process and evaluation," *WEI international European academic conference proceedings, Zagreb, Croatia.*, p. 14, 2012.
- [20] A. Holliday, *Doing and Writing Qualitative Research*. 1 Oliver's Yard, 55 City Road, London EC1Y 1SP United Kingdom: SAGE Publications Ltd, 2007. doi: 10.4135/9781446287958.
- [21] P. S. Schindler, *Business research methods*, Fourteenth edition. New York: McGraw-Hill, 2022.
- [22] R. K. Yin, Ed., *Qualitative research from start to finish*. New York: Guilford Press, 2016.
- [23] J. W. Creswell, *Research design: qualitative, quantitative, and mixed methods approaches*, 4th ed. Thousand Oaks: SAGE Publications, 2014.
- [24] "HEALTH AND FOOD SAFETY - Goodbye E171: The EU bans titanium dioxide as a food additive." Accessed: Jan. 13, 2025. [Online]. Available: <https://ec.europa.eu/newsroom/sante/items/732079/en>
- [25] "Bioconjugates Services | Lonza." Accessed: Jan. 18, 2025. [Online]. Available: <https://www.lonza.com/biologics/bioconjugates>
- [26] "Corporate Governance | Lonza," Corporate Governance | Lonza. Accessed: Jan. 15, 2025. [Online]. Available: <https://www.lonza.com/investor-relations/corporate-governance>
- [27] J. A. DiMasi, R. W. Hansen, H. G. Grabowski, and L. Lasagna, "Cost of innovation in the pharmaceutical industry," *Journal of Health Economics*, vol. 10, no. 2, pp. 107–142, Jul. 1991, doi: 10.1016/0167-6296(91)90001-4.
- [28] H. Xu and K. Chen, "Complementary and alternative medicine: Is it possible to be mainstream?," *Chin. J. Integr. Med.*, vol. 18, no. 6, pp. 403–404, Jun. 2012, doi: 10.1007/s11655-012-1126-7.
- [29] "Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications," *Ann Intern Med*, vol. 164, no. 1, p. I–28, Jan. 2016, doi: 10.7326/P16-9002.
- [30] M. McCamish, W. Yoon, and J. McKay, "Biosimilars: biologics that meet patients' needs and healthcare economics," *Am J Manag Care*, vol. 22, no. 13 Suppl, pp. S439–S442, Sep. 2016.
- [31] J. Bergsland, "Major Innovations and Trends in the Medical Device Sector," *Acta Inform Med*, vol. 20, no. 1, p. 44, 2012, doi: 10.5455/aim.2012.20.44-46.
- [32] A. Forghani, S. J. Sadjadi, and B. Farhang Moghadam, "A supplier selection model in pharmaceutical supply chain using PCA, Z-TOPSIS and MILP: A case study," *PLoS ONE*, vol. 13, no. 8, p. e0201604, Aug. 2018, doi: 10.1371/journal.pone.0201604.



- [33] “The Impact of Pharmaceutical Wholesalers on U.S. Drug Spending.” Accessed: Jan. 10, 2025. [Online]. Available: <https://www.commonwealthfund.org/publications/issue-briefs/2022/jul/impact-pharmaceutical-wholesalers-drug-spending>
- [34] A. G. M. Gad, I. O. Osarhiemen, and V. Idama, “Current Models of Innovation and Market Strategies in Pharmaceutical Development: A Comprehensive Review,” *Asian J. Res. Med. Pharm. Sci.*, vol. 13, no. 4, pp. 74–82, Nov. 2024, doi: 10.9734/ajrimps/2024/v13i4275.
- [35] G. Díaz Olmeda and J. C. Sosa Varela, “Determinants of International Competitiveness in the Pharmaceutical Industry,” *ESIC MARKET*, vol. 43, no. 2, pp. 371–385, May 2012, doi: 10.7200/esicm.142.0432.4i.
- [36] “Lonza Completes Acquisition of Capsugel to Create Leading Integrated Solutions...” Accessed: Jan. 10, 2025. [Online]. Available: <https://www.lonza.com/news/2017-07-06-05-00>
- [37] A. A. & Intelligence, “Nutraceuticals Market Size & Share, Growth Report, Forecast,” Arizton Advisory & Intelligence. Accessed: Jan. 10, 2025. [Online]. Available: https://www.arizton.comhttps://www.arizton.com/market-reports/nutraceuticals-market?utm_source=chatgpt.com
- [38] A. Bose and S. Sharma, “Global Regulatory Trends and Comparative Insights: Nutraceuticals in the USA, India, and Europe,” *PharmaNutrition*, p. 100430, Jan. 2025, doi: 10.1016/j.phanu.2025.100430.
- [39] H. B. Jadhav *et al.*, “Factors governing consumers buying behavior concerning nutraceutical product,” *Food Science & Nutrition*, vol. 11, no. 9, pp. 4988–5003, Sep. 2023, doi: 10.1002/fsn3.3518.
- [40] U. Golla, “Emergence of nutraceuticals as the alternative medications for pharmaceuticals,” *IJCAM*, vol. 11, no. 3, 2018, doi: 10.15406/ijcam.2018.11.00388.
- [41] admin, “The Advantages of Ordering Nutraceutical Products in Bulk - Ikonremedies,” Ikon Remedies. Accessed: Jan. 12, 2025. [Online]. Available: <https://www.ikonremedies.com/the-advantages-of-ordering-nutraceutical-products-in-bulk/>
- [42] R. and M. ltd, “Europe Nutraceutical Market Size, Competitors & Forecast.” Accessed: Jan. 12, 2025. [Online]. Available: <https://www.researchandmarkets.com/reports/4775076/europe-nutraceutical-market-share-analysis>
- [43] “The Nutraceuticals Industry in 2024: A Comprehensive Outlook on Growth, Profits, Market Trends, Research, and Job Opportunities - Biotrex Nutraceuticals.” Accessed: Jan. 12, 2025. [Online]. Available: https://bio-trex.com/the-nutraceuticals-industry-in-2024-a-comprehensive-outlook-on-growth-profits-market-trends-research-and-job-opportunities/?utm_source=chatgpt.com
- [44] “Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook | Lonza.” Accessed: Jan. 13, 2025. [Online]. Available: <https://www.lonza.com/news/2024-07-25-06-55>
- [45] P. N. 9 min read, “Global Hard Empty Capsule Market Forecast to Expand at a CAGR of 4.6% by 2030 - Claim Your Free Sample Report | Valuates Reports,” Yahoo Finance. Accessed: Jan. 13, 2025. [Online]. Available: <https://finance.yahoo.com/news/global-hard-empty-capsule-market-175400345.html>
- [46] “Capsules & Health Ingredients | Lonza,” Capsules & Health Ingredients | Lonza. Accessed: Jan. 15, 2025. [Online]. Available: <https://www.lonza.com/capsules-health-ingredients>
- [47] “Lonza Expands Its Capsule Manufacturing Capacity.” Accessed: Jan. 15, 2025. [Online]. Available: <https://www.lonza.com/news/2020-10-22-05-00>



- [48] ccolin, “Lonza inaugurates its innovation center in Colmar (Eastern France),” Invest Eastern France. Accessed: Jan. 15, 2025. [Online]. Available: <https://www.invest-easternfrance.com/en/lonza-inaugure-son-centre-dinnovation-a-colmar-grand-est/>
- [49] “Lonza | Our People And Culture.” Accessed: Jan. 15, 2025. [Online]. Available: <https://www.lonza.com/annualreport/2023/company/our-people-and-culture>
- [50] “The regulations governing internal organization and board committees.pdf.” Accessed: Jan. 15, 2025. [Online]. Available: <https://dam.lonza.com/dmm3bwsv3/assetstream.aspx?assetid=6850&cat=Corporate+Brand&destinationid=10016&mediaformatid=10061>
- [51] “Our Vision, Purpose and Strategy | Lonza,” Our Purpose and Strategy | Lonza. Accessed: Jan. 15, 2025. [Online]. Available: <https://www.lonza.com/about-us/strategy>
- [52] “Investor Relations | Lonza,” Investor Relations | Lonza. Accessed: Jan. 15, 2025. [Online]. Available: <https://www.lonza.com/investor-relations>
- [53] “Lonza | Investor Information.” Accessed: Jan. 15, 2025. [Online]. Available: <https://www.lonza.com/annualreport/2023/company/investor-information>